SCHEMBL25367105

SCHEMBL25367105

CC(C)(C)OC(=O)N(Cc1cc(F)ccc1Br)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SSTR4 P31391 1/20 0.40
▸ RIPK1 Q13546 3/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ HTR2C P28335 2/20 0.37
▸ SLC6A4 P31645 2/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ NR3C1 P04150 1/20 0.36
▸ KDM1A O60341 1/20 0.35
▸ MTNR1A P48039 1/20 0.34
▸ MTNR1B P49286 1/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ NR1D1 P20393 1/20 0.34
▸ KCNQ4 P56696 1/20 0.34
▸ KCNQ5 Q9NR82 1/20 0.34
▸ FFAR1 O14842 1/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34
▸ CTSS P25774 1/20 0.34
▸ CTSK P43235 1/20 0.34
▸ CPB2 Q96IY4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12715855 0.93 GRM2 (0.43) SSTR4RIPK1GRM2HTR2CSLC6A4
SCHEMBL23105683 0.84 RIPK1 (0.49) SSTR4RIPK1HTR2CSLC6A4HTR2A
SCHEMBL5773500 0.83 GRM2 (0.38) SSTR4RIPK1GRM2HTR2CSLC6A4
SCHEMBL25366767 0.83 KCNQ4 (0.50) RIPK1GRM2HTR2CSLC6A4HTR2A
SCHEMBL20971519 0.81 SSTR4 (0.39) SSTR4GRM2
SCHEMBL5191856 0.80 GRM2 (0.45) SSTR4RIPK1GRM2HTR2CSLC6A4
SCHEMBL5777536 0.79 GRM2 (0.36) RIPK1GRM2HTR2CSLC6A4HTR2A
SCHEMBL4388596 0.78 HTR2C (0.41) SSTR4RIPK1HTR2CSLC6A4HTR2A
SCHEMBL19795467 0.78 SSTR4 (0.40) SSTR4GRM2MTNR1AMTNR1BAKT1
SCHEMBL4715109 0.78 SSTR4 (0.52) SSTR4RIPK1GRM2HTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 — — US disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 SSTR4 3293/4885RIPK1 158/4885GRM2 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback